Abstract
OBJECTIVE:
Darbepoetin is longer acting and more potent than recombinant erythropoietin (rEpo). In certain situations, preterm neonates might benefit from rEpo, and for such patients darbepoetin would require fewer doses at a lower cost. However, the proper dose and dosing interval have not been established.
STUDY DESIGN:
We performed a prospective trial in two level III Neonatal Intensive Care Units. Patients <32 weeks gestation at birth, with a birth weight (BW) <1500 g, were eligible for participation if they were >21-days-old and had a hemoglobin (Hgb) concentration ≤10.5 g/dl. In all, 12 were to receive a single subcutaneous (s.c.) dose at either 1 or 4 μg/kg. Once before the dose was given, and at two preset intervals after, blood was obtained for immature reticulocyte fraction (IRF) and absolute reticulocyte count (ARC). Once before and at four preset intervals after, blood was obtained for pharmacokinetic studies.
RESULTS:
The 12 subjects had BWs of 1129±245 g (mean±SD), were 29.2±1.2 weeks gestation at delivery, and were 43±12 days old with an Hgb concentration of 9.6±1.0 g/dl when the darbepoetin was given. Six received 1 μg/kg and six 4 μg/kg. The IRF increased (p<0.05) as did the ARC (p<0.05). The increases in IRF were somewhat greater among the 4 μg/kg recipients (P=0.06). The highest recorded concentrations of drug occurred 6 to 12 hours after administration. The combined 6 and 12 hours values were 185±106 mU/ml in the 1 μg/kg group vs 597±238 in the 4 μg/kg group (p<0.002). The t½ was 26 hours (range 10 to 50). The biovailability-normalized clearance was 19 ml/hour/kg (range 5 to 54).
CONCLUSIONS:
A single s.c. dose of darbepoetin given to preterm neonates accelerated effective erythropoiesis. The pharmacodynamic and pharmacokinetic findings suggest that darbepoetin dosing in neonates would require a higher unit dose/kg and a shorter dosing interval than are generally used for anemic adults.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Egrie JC, Dwyer E, Lykos M, et al. Novel erythropoiesis stimulating protein (NESP) has a longer plasma half-life and greater in vivo biological activity than recombinant human erythropoietin. Blood 1997;99:56a.
Egrie JC, Browne JK . Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84 (Suppl.): 3–10.
Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290–299.
Ohls RK, Dai A . The effect of Aranesp on the growth of fetal and neonatal erythroid progenitors. Blood 2003;102:18b.
Ohls RK, Dai A . Long-acting erythropoietin: clinical studies and potential uses in neonates. Clin Perinatol 2004;31:77–89.
Garcia MG, Hutson AD, Christensen RD . Effect of recombinant erythropoietin on “late” transfusions in the neonatal intensive care unit: a meta-analysis. J Perinatol 2002;22:108–111.
Christensen RD, Calhoun DA, Rimsza LM, et al. A consistent approach to procedures and practices in Neonatal Hematology. Clinics in Perinatol 2000;27:733–754.
Reiter PD, Rosenberg AA, Valuck RJ . Factors associated with successful epoetin alfa therapy in premature neonates. Ann Pharmacother 2000;34:433–439.
Reiter PD, Rosenberg AA, Valuck A, Novak K . Effect of short-term erythropoietin therapy in anemic premature neonates. J Perinatol 2005;25:125–129.
Davis BH, Ornvold K, Bigelow NC . Flow cytometric reticulocyte maturity index: a useful laboratory parameter of erythropoietic activity in anemia. Cytometry 1995;22:35–39.
Smith Jr RE, Tchekmedyian NS, Chan D, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851–1858.
Kotasek D, Steger G, Faught W, et al. Aranesp 980291 Study Group. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026–2034.
Lerner G, Kale AS, Warady BA, et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatri Nephrol 2002;17:933–937.
De Palo T, Giordano M, Poalumbo F, et al. Clinical experience with darbepoetin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004;19:337–340.
Donato H, Vain N, Rendo P, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants; results of a randomized, placebo-controlled, multicenter trial. Pediatrics 2000;105:1066–1072.
Ohls RK, Harcum J, Schibler KR, Christensen RD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams of less. A randomized, double blind, placebo-controlled study. J Pediatr 1997;131:661–665.
Ohls RK, Veerman MW, Christensen RD . Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition. J Pediatr 1996;128:518–523.
Meyer MP, Meyer JH, Commerford A, et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity; results of a double blind, placebo-controlled study. Pediatrics 1994;93:918–923.
Maier RF, Obladen M, Kattner E, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. The European multicentere rhEpo study group. J Pediatr 1998;132:866–870.
Brugnara C . Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 1998;28:1–11.
Lesesve JF, Lacombe F, Marit G, Bernard P, Belloc F, Reiffers J . High fluorescence reticulocytes are an indicator of bone marrow recovery after chemotherapy. Eur J Haematol 1995;54:61–63.
Ohls RK . Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity. Paediatr Drugs 2002;4:111–121.
Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW . Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993;21:635–642.
Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392–2395.
Acknowledgements
We thank the NICU staff nurses at McKay-Dee Hospital and LDS Hospital for their valuable help with this study.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Warwood, T., Ohls, R., Wiedmeier, S. et al. Single-Dose Darbepoetin Administration to Anemic Preterm Neonates. J Perinatol 25, 725–730 (2005). https://doi.org/10.1038/sj.jp.7211387
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7211387
This article is cited by
-
Darbepoetin Alfa for Late-onset Anemia in Neonates with Rhesus Hemolytic Disease
Indian Journal of Pediatrics (2023)
-
Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial
Pediatric Research (2015)
-
Why do four NICUs using identical RBC transfusion guidelines have different gestational age-adjusted RBC transfusion rates?
Journal of Perinatology (2015)
-
Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Clinical Pharmacokinetics (2015)
-
Estimating the nucleated red blood cell ‘emergence time’ in neonates
Journal of Perinatology (2014)